Table 2.
LMO1 gene polymorphisms and neuroblastoma susceptibility in eastern Chinese population.
| Genotype | Cases (n = 313) | Controls (n = 762) | Pa | Crude OR (95% CI) | P | Adjusted OR (95% CI)b | Pb |
|---|---|---|---|---|---|---|---|
| RS110419 (HWE = 0.405) | |||||||
| AA | 150 (47.92) | 279 (36.61) | 1.00 | 1.00 | |||
| AG | 118 (37.70) | 355 (46.59) | 0.62 (0.46–0.82) | 0.0011 | 0.62 (0.46–0.82) | 0.0010 | |
| GG | 45 (14.38) | 128 (16.80) | 0.65 (0.44–0.97) | 0.034 | 0.65 (0.44–0.97) | 0.035 | |
| Additive | 0.0026 | 0.76 (0.63–0.92) | 0.0041 | 0.76 (0.63–0.92) | 0.0040 | ||
| Dominant | 163 (52.08) | 483 (63.39) | 0.0006 | 0.63 (0.48–0.82) | 0.0006 | 0.63 (0.48–0.82) | 0.0006 |
| Recessive | 268 (85.62) | 634 (83.20) | 0.326 | 0.83 (0.58–1.20) | 0.327 | 0.83 (0.58–1.21) | 0.334 |
| RS4758051 (HWE = 0.530) | |||||||
| GG | 138 (44.09) | 256 (33.60) | 1.00 | 1.00 | |||
| AG | 123 (39.30) | 364 (47.77) | 0.63 (0.47–0.84) | 0.0017 | 0.62 (0.47–0.84) | 0.0015 | |
| AA | 52 (16.61) | 142 (18.64) | 0.68 (0.47–0.99) | 0.046 | 0.67 (0.46–0.99) | 0.042 | |
| Additive | 0.0048 | 0.78 (0.65–0.94) | 0.0094 | 0.78 (0.64–0.94) | 0.0085 | ||
| Dominant | 175 (55.91) | 506 (66.40) | 0.0012 | 0.64 (0.49–0.84) | 0.0012 | 0.64 (0.49–0.84) | 0.0011 |
| Recessive | 261 (83.39) | 620 (81.36) | 0.434 | 0.87 (0.61–1.23) | 0.434 | 0.87 (0.61–1.23) | 0.417 |
| RS10840002 (HWE = 0.981) | |||||||
| AA | 120 (38.34) | 240 (31.50) | 1.00 | 1.00 | |||
| AG | 128 (40.89) | 375 (49.21) | 0.68 (0.51–0.92) | 0.012 | 0.68 (0.50–0.91) | 0.011 | |
| GG | 65 (20.77) | 147 (19.29) | 0.88 (0.61–1.27) | 0.509 | 0.88 (0.61–1.27) | 0.491 | |
| Additive | 0.036 | 0.90 (0.74–1.08) | 0.264 | 0.90 (0.75–1.08) | 0.251 | ||
| Dominant | 193 (61.66) | 522 (68.50) | 0.031 | 0.74 (0.56–0.97) | 0.031 | 0.74 (0.56–0.97) | 0.028 |
| Recessive | 248 (79.23) | 615 (80.71) | 0.581 | 1.10 (0.79–1.52) | 0.581 | 1.10 (0.79–1.52) | 0.589 |
| RS204938 (HWE = 0.336) | |||||||
| AA | 200 (63.90) | 476 (62.47) | 1.00 | 1.00 | |||
| AG | 97 (30.99) | 258 (33.86) | 0.90 (0.67–1.19) | 0.446 | 0.91 (0.68–1.21) | 0.498 | |
| GG | 16 (5.11) | 28 (3.67) | 1.36 (0.72–2.57) | 0.343 | 1.34 (0.71–2.54) | 0.368 | |
| Additive | 0.418 | 1.00 (0.79–1.26) | 1.000 | 1.01 (0.80–1.27) | 0.969 | ||
| Dominant | 113 (36.10) | 286 (37.53) | 0.659 | 0.94 (0.72–1.24) | 0.659 | 0.95 (0.72–1.25) | 0.709 |
| Recessive | 297 (94.89) | 734 (96.33) | 0.280 | 1.41 (0.75–2.65) | 0.282 | 1.39 (0.74–2.61) | 0.311 |
| RS2168101 (HWE = 0.389) | |||||||
| GG | 214 (68.37) | 401 (52.62) | 1.00 | 1.00 | |||
| GT | 85 (27.16) | 310 (40.68) | 0.51 (0.38–0.69) | <0.0001 | 0.50 (0.38–0.67) | <0.0001 | |
| TT | 14 (4.47) | 51 (6.69) | 0.51 (0.28–0.95) | 0.034 | 0.52 (0.28–0.96) | 0.036 | |
| Additive | < 0.0001 | 0.59 (0.47–0.75) | <0.0001 | 0.59 (0.46–0.74) | <0.0001 | ||
| Dominant | 99 (31.63) | 361 (47.38) | < 0.0001 | 0.51 (0.39–0.68) | <0.0001 | 0.51 (0.38–0.67) | <0.0001 |
| Recessive | 299 (95.53) | 711 (93.31) | 0.165 | 0.65 (0.36–1.20) | 0.169 | 0.66 (0.36–1.21) | 0.182 |
| COMBINED EFFECT OF PROTECTIVE GENOTYPESC | |||||||
| 0–3 | 213 (68.05) | 401 (52.62) | 1.00 | 1.00 | |||
| 4–5 | 100 (31.95) | 361 (47.38) | < 0.0001 | 0.52 (0.40–0.69) | < 0.0001 | 0.51 (0.39–0.68) | < 0.0001 |
a
χ2 test for genotype distributions between neuroblastoma patients and controls.
b
Adjusted for age and gender.
c
Protective genotypes were rs110419 AG/GG, rs4758051 AG/AA, rs10840002 AG/GG, rs204938 AG/GG, and rs2168101 GT/TT.
The results were in bold if the 95% CI excluded 1 or P < 0.05.